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MINDFUL MEDITATION AND MOBILIZATION; PULMONARY 
REHABILITAITON FOR EMPHYSEMA PATIENTS  
HANIA ALEXANDRA ALEXANDER  
ABSTRACT 
Background summary  
 Pulmonary rehabilitation programs are an important component of the 
multidisciplinary approach to minimizing the symptomatology of patients with chronic 
obstructive pulmonary disease. Within the program, patients learn about how to live with 
their non-curable disease and how to minimize exacerbations. Although patients learn 
about their disease process, breathing techniques, and exercise, there are no specific 
components that bridge the mind and body gap to promote mindfulness through the 
patients’ efforts within the program.  
 
Literature review findings  
 This thesis contains a comprehensive literature review composed largely of 
randomized trials. These trials and studies summarize the framework of pulmonary 
rehabilitation programs and how yoga is implemented within treatment options for 
chronic diseases. The literature review highlights that pulmonary rehabilitation programs 
improve the quality of life in patients with emphysema through patient education on 
breathing and exercise. However, there is a lack of literature on the use of yoga 
techniques of breathing and exercise within the framework of pulmonary rehabilitation 




 This thesis proposes a randomized controlled study to identify a more mindful 
approach to a pulmonary rehabilitation program for emphysema patients through the use 
of timed ujjayi pranayama (mindful breathing) and yoga asanas (poses).   
 
Conclusions  
 The results will be analyzed to determine if yoga techniques lead to statistically 
significant improvement in patient outcomes in emphysema patients enrolled in a 
pulmonary rehabilitation program. 
 
Significance  
 The compiled data will reveal how yoga breathwork and movement will be 
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Chronic obstructive pulmonary disease (COPD) is an overarching medical term used to 
describe a spectrum of obstructive pulmonary diseases that affect many individuals. This 
spectrum of diseases includes asthma, chronic bronchitis, bronchiectasis, and 
emphysema. It is the fourth leading cause of death in the United States, and the annual 
costs of care are continuously rising.1 COPD is considered the “smoker’s disease”, and 
while this applies to about 75% of COPD patients, 15% of COPD patients are non-
smokers.1 While exposure to smoking is the number one risk factor for developing 
COPD, other risk factors include genetic factors, such as alpha-1 antitrypsin deficiency, 
environmental factors, such as air pollution, and a history of childhood respiratory 
infections.1 As the spectrum of disease progresses, the lungs develop airway 
inflammation, smooth muscle hyperplasia and hypertrophy, and hyperinflation.2 This 
leads to air trapping, as seen in emphysema patients. Air trapping leads to many 
complications of COPD, which affects the physiology of the individual, leads to 
premature morbidity, and increases mortality.3 All therapies utilized in COPD patients act 
to manage symptoms as opposed to providing a cure for the disease. These therapies 
include smoking cessation, bronchodilators, oxygen supplementation, pulmonary 
rehabilitation programs (PRP), nutrition and psychology counseling, and lung volume 
reduction surgery (LVRS).4 Along with being the first therapy option a patient with 
COPD should undertake, the most effective method to prevent COPD is smoking 
cessation, independent of the length of time the individual has been smoking.5 Smoking 
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cessation will decrease the amount of inflammation within the lung parenchyma, 
decreasing the amount of physiological changes in the respiratory tract. Since COPD is a 
systemic disease, it is associated with other co-morbidities, such as lung cancer and 
venous thromboembolisms.1 Lung cancer diagnosis in a COPD patient is six times more 
common than in an otherwise healthy patient.1 COPD patients are also at an increased 
risk for having anxiety and depression.6,7 A patient with a diagnosis of COPD, along with 
these multiple co-morbidities, has increased healthcare costs and a negatively affected 
quality of life.  
 
Statement of the Problem 
There is well-documented research supporting pulmonary rehabilitation programs as part 
of the multidisciplinary approach to minimizing the symptoms COPD patients experience 
during the progression of their disease.3 Pulmonary rehabilitation programs have been 
shown to improve exercise tolerance and overall quality of life among these patients.3,8–11 
During the program, patients perform various exercises, such as walking on a treadmill, 
using an indoor cycle machine, and free weights. The patients also attend lectures about 
their disease process. While all of these resources are beneficial, there is one component 
missing that has been found to be beneficial to a patient’s cardiovascular system and 
overall sense of well-being, a yoga technique used for breathing and exercise.12–15 In 
healthy individuals, yoga has been found to improve peak expiratory flow rate and forced 
expiratory volume.16 Yoga has also been used in the rehabilitation of cardiovascular and 
neurological health, by lowering diastolic blood pressure, high-density lipoprotein (HDL) 
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cholesterol, triglyceride, and anxiety levels.17–20 However, there is very limited research 
combining the use of yoga within a pulmonary rehabilitation program.  
 
Hypothesis 
Utilizing timed ujjayi pranayama coupled with chair yoga sequences in a pulmonary 
rehabilitation program will improve emphysema patients’ exercise tolerance, stationary 
breathing, and overall health quality of life.  
 
Objectives and specific aims 
As part of a multidisciplinary approach to emphysema patients, pulmonary rehabilitation 
programs have been utilized to provide patient education on their disease process, and 
improve their quality of life by increasing exercise tolerance and breathing capacity. The 
programs also provide a social setting where they can interact amongst peers with the 
same disease process. Since emphysema has no cure and is a progressive disease, 
providing tools to implement mindfulness into the program may ensure the success of the 
program’s objectives, improve the patients’ attitudes towards their disease, and motivate 
them to maintain the skills they learned through their rehabilitation program into their 
daily life. Specifically, this study aims to: 
• Implement timed ujjayi pranayama and chair yoga sequences into a pulmonary 
rehabilitation program for emphysema patients.  
• Educate emphysema patients of the benefits of a mindful approach to the 
techniques learned through the pulmonary rehabilitation program.  
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• Measure emphysema patients’ improvements in exercise tolerance, stationary 
breathing, and overall health quality of life after utilizing techniques learned in 




REVIEW OF THE LITERATURE 
Overview 
Chronic Obstructive Pulmonary Disease  
Chronic obstructive pulmonary disease is an overarching disease that includes chronic 
bronchitis, bronchiectasis, emphysema, and asthma. Asthma is included as patients with a 
history of asthma may develop COPD overtime.1 COPD is a disease that affects about 
five percent of the United States population with 12.1 million patients diagnosed over the 
age of 18.21 This disease is the third leading cause of death, following cancer and 
cardiovascular disease. While men are more likely to be affected by COPD, women are 
more at risk to die from the disease with women representing 52.3% of all COPD deaths 
in 2009.21 Two main risk factors lead to the development of COPD, environmental 
factors and genetic factors. The most important environmental factor is smoking with 
eighty to ninety percent of COPD deaths related to smoking.21 While males who smoke 
are twelve times more likely to die than males who do not smoke, female smokers are 
thirteen more times likely to die than females who do not smoke.21 Other environmental 
factors include second-hand smoke, occupational work exposures, air pollution, and 
socioeconomic status.21 Genetic factors include alpha-1 antitrypsin deficiency (AATD), 
chromosome 4 and 15 abnormalities, and a history of childhood pulmonary diseases or 
previous pulmonary diseases, including chronic bronchitis, emphysema, and asthma.1   
In additional to the individual health effects of COPD, COPD is estimated to cost 
the economy about $50 billion a year.21 In 2010, the National Heart Lung and Blood 
Institute reported that COPD accounted for $29.5 billion in direct health care 
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expenditures, $12.4 billion in indirect mortality costs, and $8 billion in indirect morbidity 
costs.21    
Similarities among the pulmonary diseases that may lead to the final diagnosis of 
COPD, including chronic bronchitis, emphysema, and asthma, are that these diseases are 
known as obstructive pulmonary diseases.5 The pathophysiology is usually due to an 
external irritant to the lung parenchyma that leads to destruction of various pulmonary 
structures.22 Airflow becomes limited and progressively results in pulmonary obstruction 
that leads to the initial presenting symptoms of dyspnea and productive cough. The 
irritants lead to a chronic inflammatory response, resulting in permanent changes to the 
lung parenchyma. The pathology of COPD can be divided into small airway disease and 
parenchyma destruction.23 Small airway disease progresses due to airway inflammation, 
fibrosis, and luminal plugs. This is seen in chronic bronchitis, which is associated with 
continuous inflammation, and results in thickening and increased mucus production 
within the airways.24 Parenchymal destruction leads to alveolar detachment from the 
bronchial tree with a resultant decrease in elastic recoil. This is seen in emphysema, 
where alveoli lose their ability to recoil, causing stiffening of air sacs that may break and 
result in air trapping.25 The loss of alveolar attachment also leads to early bronchiolar 
collapse, particularly during exhalation. This results in poor air movement within the 
alveoli and bronchioles of the lower lungs, causing to poor oxygen and carbon dioxide 
exchange, and increased air trapping. Over time, more air will be trapped within the 
broken and enlarged air sacs, resulting the initial presenting symptoms of dyspnea, 
productive cough, wheezing, and decreased exercise tolerance.26  
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While 12.1 million people over the age of 18 have been officially diagnosed with 
COPD, it is estimated that 24 million people have COPD with many having not been 
diagnosed.26 Based on surveys on presenting symptoms, such as dyspnea, dyspnea on 
exertion (DOE), productive cough, and wheezing, it is clear that COPD is being 
underdiagnosed.21 This underestimation of COPD patients skews the predicted overall 
effect of COPD on the population as a whole in regards to the expenses, maintenance, 
and appropriate resources readily available for those who need aid during COPD 
maintenance or exacerbation episodes. During a COPD exacerbation, patients experience 
an acute onset of worsening of their baseline symptoms of dyspnea and productive 
cough.27 Risk factors for the onset of an acute exacerbation include a change in the 
current medication regime or infections in the upper respiratory tract and 
tracheobronchial tree. Exacerbations usually lead to hospital admissions, increases in cost 
of care, and a change in the patient’s current treatment regimen.  
 A diagnosis of COPD is based upon the patient’s medical history, clinical 
presentation, physical exam, results of pulmonary function tests, and other tests. In 
clinically stable patients, spirometry is used to measure the pre- and post-bronchodilator 
response of forced expiratory volume in one second over forced vital capacity 
(FEV1/FVC). Forced expiratory volume is the forced expiration for one second (FEV1). 
Force vital capacity (FVC) is the amount of air that can be expelled after taking the 
deepest breath possible. To fulfill a diagnosis of COPD, the patient has to have a 
FEV1/FVC ratio less than 0.70.28 The guideline for diagnosing a patient with COPD is the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD classification) which 
	
8 
determines the disease grade and appropriate stage of treatment for the patient.29,30 The 
GOLD classification is categorized as grades GOLD 1 through GOLD 4 when a patient 
has a spirometry value of FEV1/FVC <70%.28 GOLD 1 is considered a mild severity with 
FEV1 greater than or equal to 80% predicted. GOLD 2 is considered a moderate severity 
with FEV1 less than 80% predicted and greater than or equal to 50% predicted. GOLD 3 
is considered a severe severity with FEV1 less than 50% predicted and greater than or 
equal to 30% predicted. GOLD 4 is considered a very severe severity with FEV1 less than 
30% predicted (Table 1). 
Table 1. GOLD Criteria: Airflow Limitation Severity  
GOLD Stage I  
 
[Mild] 
GOLD Stage II  
 
[Moderate] 
GOLD Stage III  
 
[Severe] 




FEV1/FVC < 0.70 
FEV1 ≥ 80% 
Predicted  
Spirometry  
FEV1/FVC < 0.70 
50% ≤ FEV1 < 
80% Predicted  
Spirometry  
FEV1/FVC < 0.70 
30% ≤ FEV1 < 
50% Predicted  
Spirometry  
FEV1/FVC < 0.70 
FEV1 < 30% 
Predicted or  
FEV1 < 50% 
Predicted and 
Chronic 





cough and sputum 
production  
Symptoms  
Worsening airflow  
Shortness of breath 





of breath  
Reduced quality of 
life  
Symptoms  





quality of life  
 
Patients are then further categorized into another set of four groups ranging from 
Group A to Group D based upon airflow restriction, symptom score, and number of 
exacerbations within one year.31 Patients who are classified as mild to moderate grades 
are categorized into group A or B. Patients who are classified as severe to very severe 
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grades are categorized into group C or D. The airflow restriction classification system 
accounts for the objective measurements of diagnosing COPD. This is accomplished with 
the measurement of FEV1, as supported by the American College of Physicians.32 
Subjective measurements are accomplished through patient survey responses to the 
COPD Assessment Test (CAT) and the modified Medical Research Council Dyspnea 
Scale (mMRC) as supported by the National Institute for Health and Care Excellence 
guideline.31 These patient surveys are used to determine the patient’s symptom score. For 
example, the mMRC asks the patient to determine their level of breathlessness on a scale 
of 0 to 4 with 0 is equivalent to becoming breathless with strenuous exercise and 4 is 
equivalent to becoming breathless with dressing. The CAT assesses for daily symptoms 
of cough, phlegm, chest tightness, associated breathlessness with climbing stairs and 
completing household chores, sleep quality, energy levels, and confidence of leaving the 
house due to the disease. To be assigned to group A or C, patients must have a CAT score 
of less than 10 and a mMRC score of 0 or 1. To be assigned to group B or D, patients 
must have a CAT score of greater than or equal to 10 and a mMRC score of greater than 
or equal to 2 (Table 2). It is important to combine the information obtained from both the 
objective and subjective methods for the measurement of FEV1, as airflow obstruction 
may not always correlate well with the patient’s clinical presentation and, ultimately, the 
accuracy of their diagnosis. Lastly, the number of COPD exacerbations the patient 
experiences in a given year are recorded and complete the final step in assigning a GOLD 
group to the patient. Tables 1 and 2 represent the combined approach to diagnosing and 
categorizing COPD patients.  
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Table 2. GOLD Criteria: Symptom Assessment and Risk of Exacerbations 











Table Heading Abbreviations: mMRC=modified Medical Research Council 
Dyspnea Scale, CAT=COPD Assessment Test 
 
Treatment for COPD is not curative, but is rather focused on symptom 
management, exacerbation prevention, and ongoing lung injury prevention. This 
multidisciplinary approach includes smoking cessation, preventative measures with 
vaccinations, symptom-based therapy of inhaled and oral medications, oxygen 
supplementation, outpatient pulmonary rehabilitation programs, nutritional counseling, 
psychological counseling, and surgery.33 Taking the time to categorize a patient into the 
correct GOLD group is important because the group determines the stepwise method in 
which treatment begins and progresses.  
However, all should be educated on smoking cessation and provided the tools to 
help them succeed in cessation and maintenance.5,26,31,33 Some of these tools include 
various forms of counseling and behavior therapies, along with pharmacotherapies. It is 
best to individualize the process to the patient, and combine all the support systems the 
patient may need. Combined pharmacotherapy and counseling have the best success rates 
for smoking cessation. 
The pharmacologic agents used in COPD can be divided into inhaled medications 
and oral medications.31 Patients who are in Group A are prescribed a short-acting beta-2 
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agonist, such as albuterol, levalbuterol, or pirbuterol, which improve lung function, 
dyspnea, and fatigue. Another option is a short-acting anticholinergic, such as 
ipratropium. Both of these options are used on an as needed basis with mild intermittent 
symptoms. If the patient is in Group B, a long-acting beta-2 agonist, such as arformoterol, 
formoterol, indacaterol, and salmeterol are added to the regimen. These agents act as 
bronchodilators, improving FEV1 and symptom scores, and decrease acute exacerbations. 
Long-acting anticholinergics can also be used, such as tiotropium or aclidinium. 
Tiotropium has been shown to decrease acute exacerbations and improve patient’s quality 
of life.31 Combination therapy with a long-acting beta-2 agonist and a long-acting 
anticholinergic can be used when one does not achieve the desired effect in patient 
symptom improvement utilizing a single medication. Group C and D step-up 
management includes using a long-acting anticholinergic medication or a combination of 
a long-acting beta-2 agonist and an inhaled corticosteroid. Patients who have had 
difficulty managing their symptoms can go on a triple therapy regimen of a long-acting 
beta-2 agonist, long-acting anticholinergic, and an inhaled corticosteroid.  
Oral medications that may be used in symptom management in COPD include 
theophylline and roflumilast. Theophylline is an oral phosphodiesterase inhibitor that acts 
as a bronchodilator to relax smooth muscles, improve diaphragm contractility, increase 
mucociliary transport, and reduce edema. Roflumilast is an oral phosphodiesterase-4 
inhibitor mostly utilized in patients who have chronic bronchitis or as long-acting 
bronchodilator within groups C and D. Addition of these medications may be considered 
in patients who are not well-controlled on inhaled medications.  
	
12 
The primary intervention to prevent COPD development, progression, and 
exacerbations is smoking cessation.1,33 Regardless of the length of time the patient has 
been smoking, it has been shown that smoking cessation will decrease the rapid rate of 
pulmonary function deterioration and result in preserved lung function, improved 
symptoms, and improved mortality.1,18,27 Success in smoking cessation is achieved by 
developing patient trust during the medical interview process and establishing the 
motivating and pleasurable factors behind the patient’s decision to smoke. By 
establishing that foundation, the provider and the patient are able to establish a trusting 
partnership in the efforts to cease smoking. Smoking cessation can be accomplished in a 
variety of ways and it is best to work with the patient and their needs regarding how they 
would like to approach this challenge. A great resource regarding smoking cessation is 
the American Lung Association (ALA), which offers self-help books, support groups, 
chat rooms, and other resources to aid in the cessation of smoking.21 Pharmacotherapies 
include medications that decrease nicotine cravings and withdrawals. These include the 
nicotine patch, nicotine gum, nicotine inhaler, nicotine nasal spray, sustained release 
bupropion, and varenicline.34  
Supplemental oxygen can be used as therapy and also as a preventative approach 
to decrease the number of COPD exacerbations that occur yearly. Patients are candidates 
for oxygen supplementation when their partial pressure of oxygen measured in the 
arterial blood (PaO2) is less than 55 mmHg or oxygen saturation measured as the oxygen 
bound to hemoglobin in arterial blood (SaO2) is less than 88% on room air.35 Patients also 
qualify for oxygen supplementation if they have cor pulmonale with a PaO2 56 to 59 
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mmHg or SaO2 89% on room air.35 The benefits of oxygen supplementation include an 
increase in life span associated with the improvement in chronic hypoxemia. Oxygen 
supplementation also results in a decrease in the hematocrit and improvement in 
pulmonary hemodynamics. Oxygen supplementation improves neuropsychology and 
improves exercise endurance when used as long-term therapy. The goal of oxygen 
supplementation is to provide enough oxygen to achieve 90% oxygen saturation and to 
prevent respiratory acidosis.35  
Patients should also receive the recommended vaccinations for influenza annually 
and pneumococcal pneumonia after the age of 19.31 Lastly, the patient should control 
environmental irritants to decrease the potential for chronic irritation and inflammation of 
the lung parenchyma. 
The long-term prognosis of patients diagnosed with COPD is estimated based 
upon the BODE index, which incorporates the patient’s body mass, airflow obstruction, 
dyspnea, and exercise capacity.36 This index takes all four factors into consideration 
when determining the COPD severity level and estimates one to two to four-year 
survival. It is also important to take into consideration the patient’s other co-morbidities 
that may be affecting their COPD disease progression.  
 
Emphysema  
Emphysema is the most common lung disease of the lung parenchyma. This obstructive 
lung disease is a long-term, slowly progressive disease where the lung parenchyma of the 
various structures of the respiratory tract are destroyed due to elastin loss. This leads to 
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damage of the respiratory bronchioles, alveolar ducts, alveolar sacs, and the alveoli and, 
therefore, affects the efficiency of breath by flow reduction. There is a lifetime 
prevalence rate of 20.2 per 1,000 persons and about 93% of the four million patients 
diagnosed with emphysema are 45 years old or older.21 After the age of 40, the risk of 
being diagnosed with COPD doubles.21 More specifically, emphysema is more prevalent 
in non-Hispanic Caucasians with 3.8 million diagnosed with emphysema in 2011.21 In 
2011, there was also an increase in non-Hispanic African Americans who were diagnosed 
with emphysema, with 489,000 patients, leading to 17.9 persons per 1,000.21 Emphysema 
is less prevalent among Hispanics and other non-Hispanics; there are 232,000 Hispanic 
patients, equivalent to 7.1 per 1,000 persons, and 178,285 other non-Hispanic patients, 
which is equivalent to 13.4 per 1,000 persons.21 In regards to gender, the prevalence of 
women diagnosed with emphysema increased by 63%, passing that of men, which 
increased by 6%, in 2011.21 The prevalence of women in 2011 was 2.5 million patients, 
or  21.4 per 1,000 persons, while men was 2.1 million patients, or 19.0 per 1,000 
persons.21 Within the umbrella of COPD, emphysema is responsible for more deaths 
when compared to chronic bronchitis. Paralleling the trend in prevalence, the age-
adjusted death rate is higher amongst non-Hispanic Caucasians when compared to non-
Hispanic African Americans and Hispanics.21 The age-adjusted death rate in non-
Hispanic Caucasians was 5.1 per 100,000 persons, while it was 2.8 per 100,000 persons 
for non-Hispanic African Americans and 1.6 per 100,000 persons for Hispanics.37  
Known risk factors that increase the risk of developing COPD are genetic factors 
and environmental factors. The only known genetic factor that leads to the development 
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of emphysema is AATD.38 Alpha-1 antitrypsin (AAT) is a glycoprotein, also called 
alpha-1 protease inhibitor, and is coded by chromosome 14. It is a protein that is 
produced in the liver and functions to protect the lung parenchyma. In the absence of 
AAT, there is an increase in neutrophil elastase, which leads to an imbalance of protease 
and antiprotease. This can increase the risk of developing emphysema, which is usually 
seen after the age of 25 in smokers. AAT deficiency accounts for about one percent of all 
emphysema patients.39 Other risk factors for the development of emphysema include 
environmental factors, such as smoking, and other irritants, including second-hand 
smoke, air pollution, and childhood respiratory infections.1 
Emphysema is characterized by the pathophysiological mechanisms by evidence 
of airflow reduction and air trapping. Airflow obstruction occurs due to the loss of 
alveolar attachments to the terminal bronchioles leading to early bronchiolar closing. 
Environmental and genetic risk factors cause progressive irreversible damage, which 
leads to the loss of elastin within the lung parenchyma. This decreases the ability of the 
respiratory tract to recoil, preventing the alveoli to remain open. In addition, there is loss 
of alveolar surface area, which leads to impaired gas exchange with resultant poor 
oxygenation of the blood and carbon dioxide retention. Histologically, the location of the 
lung parenchymal destruction can be divided by lung locations into upper lung, or 
centrilobular, and lower lung, or panlobular.40 Centrilobular emphysema is associated 
with a history of heavy smoking, while panlobular emphysema is more strongly 
associated with AAT deficiency. Overall, emphysema is a disease of loss of elastin, 
where elastin is degraded and an increase in proteolysis from elastase without obvious 
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signs of fibrosis.41 Smoking is an important risk factor because it increases 
polymorphonuclear leukocytes and membrane attack complexes, which increases the 
production of elastase and, therefore, elastin destruction. While the lung parenchyma will 
try to repair itself, over time, it is unable to and airflow is limited.  
Dynamic hyperinflation, or “air trapping”, is a major pathophysiologic process in 
emphysema. The elastin homeostasis hypothesis suggests that an imbalance of elastases, 
which degrade elastin, and anti-elastases, which prevent elastin degradation by repair 
mechanisms, may be the etiology behind loss of alveolar attachments and decrease in 
elastic recoil.42 This leads to an overall increase in lung volumes in patients with 
emphysema. The loss of alveolar attachments along the bronchioles leads to early closure 
of the bronchioles during exhalation. This early closure prevents the lungs from reaching 
functional residual capacity. Following each breath, a small volume of air is “trapped” 
within the lung, rather than being exhaled out as it should be. Patients with emphysema 
have a significant increase in their residual volume (RV), a slight increase in their 
functional residual capacity (FRC), and a decrease in their total lung capacity (TLC), 
which leads to an overall decrease in space to breath.36 Air becomes trapped within the 
alveoli that have lost the ability to recoil, which is observed in the disease progression 
over a period of years. Eventually, as the disease progresses, the patient will be trapping 
air at rest, where there is static hyperinflation of the lungs.35 In this state, the lungs have 
less recoil pressure to counteract the chest wall recoil pressure, leading to a balance of 
equilibrium at a higher resting lung volume when compared to a normal, healthy baseline 
lung volume. As the disease progresses even more, there will be additional air trapping 
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during the beginning of exercise, which leaves the patient short of breath as the lungs 
experience dynamic hyperinflation.35 In this state, there is an imbalance between the 
volume of the inhaled air and the volume of the exhaled air, leading to an increase in air 
trapping. Emphysema patients have less time to exhale the air out of their lungs due to 
the limitations in their quality of airflow. Dynamic hyperinflation becomes worse in 
situations that demand an increase in airflow, such as during a COPD exacerbation, or 
during normal exercise.43 Dynamic inflation leads to significant dyspnea and patients 
with emphysema have limited exercise capacity due to dynamic hyperinflation.  
As a consequence of the dyspnea, emphysema patients have a decrease in exercise 
tolerance. Emphysema patients exercise less due to dyspnea, leading to deconditioning 
and a further reduction in exercise capacity. Gradually, patients will develop increasing 
DOE with physical activities that previously did not cause them discomfort or require 
extra physical or breathing efforts. This process will eventually deter patients from 
engaging in basic physical activities, such as light exercise, walking greater than six feet, 
or lifting heavy objects. While the normal process of aging may cause patients to alter 
their daily physical activity, having emphysema will accelerate this decline.  
Over time, emphysema patients are described as a “pink puffer”.3 This description 
is based upon their long-term clinical symptoms and the effects these symptoms have on 
the physical body. Patients become thin, appearing almost cachectic in appearance, and 
have a pink hue to their skin tone and a barrel-shaped torso, which is due to the 
hyperinflation occurring at the level of the alveoli within the lungs. This hyperinflation 
increases intrathoracic pressures and reduces cardiac function by reducing venous return 
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to the heart with a resultant decrease in ventricular volume and stroke volume (SV).39 
They will also have increased accessory muscle use associated with their breathing, since 
they are trying to overcome the increase in their minute ventilation (MV).2 This will 
eventually lead to respiratory muscle fatigue and ultimately an inability to generate good 
quality air flow. 
A diagnosis of emphysema is based upon the history of symptoms, physical 
examination, pulmonary function testing (PFT), imaging with chest X-ray (CXR) or 
computed tomography (CT) scan, and arterial blood gas (ABG) testing. On physical 
exam, the patient will have diminished breath sounds, pursed lip breathing with accessory 
muscle use, and a barrel-shaped chest. As the disease progresses, the patient can develop 
signs and symptoms of right-sided heart failure (HF) with an increased second pulmonic 
heart sound, tricuspid regurgitation (TR), elevated jugular venous distention (JVD), 
hepatomegaly, and edema. If an ABG is obtained when the patient is admitted to the 
hospital for an exacerbation, the ABG can be normal or show that the patient is hypoxic. 
Pulmonary function testing measures the flow of air in and out of the patient’s lungs over 
time. A patient with emphysema will have a decrease in FVC, FEV1, and FEV1/FVC.44 
The patient will also have a decrease in vital capacity (VC), which is the amount of 
exhaled air after a full inhalation. RV will increase, which is the amount of air remaining 
in the lungs after a full exhalation. The RV increases in emphysema due to early closure 
of the bronchioles during exhalation, which prevents complete emptying of the alveoli at 
the end of exhalation. The destruction of the alveolar gas exchange surface in emphysema 
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also leads to a loss of the associated capillary bed, leading to a decrease in the diffusion 
capacity of the lung for carbon monoxide (DLCO).45  
EKG findings noted in obstructive lung disease may show evidence of right atrial 
enlargement and right heart strain. A CXR will show a flattened diaphragm and 
peripheral vascular pruning.46 Chronic hypoxia leads to a series of physiological changes, 
including remodeling and destruction of the pulmonary vessels, resulting in peripheral 
vascular pruning and compression of the vascular bed.39 
While it will not reverse the disease, smoking cessation diminishes inflammation 
and oxidative stress, which can decrease the number of exacerbations for a patient. There 
are some studies that show smoking cessation decreases the number of neutrophils and 
macrophages, both located within respiratory epithelium, leading to an improvement in 
FEV1.5 This can decrease the number of proteases released that, when present, lead to 
connective tissue breakdown. In patients who continue to smoke, there is an increase in 
pigmented macrophages (MACs) within the lung.5 These pigmented MACs remove the 
debris of the damaged connective tissue, while leading to hypertrophy of mucus glands 
and, therefore, excessive mucus production.5 This leads to the collection of mucus as 
plugs, which can block small airways. In this setting, the lung parenchyma transforms 
from columnar mucosa to a premalignant dysplastic surface. This detrimental process can 
be slowed by smoking cessation and, in early cases of the disease, provide some 
regression. Within six months to one year of smoking cessation, there will be a decrease 
in neutrophils, macrophages, columnar cells, and mucus production.5 
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Besides prevention, therapies that are utilized to optimize the function of patients 
with emphysema include nutritional evaluation, oxygen supplementation, antibiotics, 
pulmonary rehabilitation clinics, bronchodilators, inhaled corticosteroids, AAT 
replacement therapy, and evaluation for LVRS or lung transplantation.3 These are not 
curative treatments; however, they aid to reduce lung hyperinflation to allow for more air 
movement. There have been newer therapies explored to reduce lung hyperinflation and 
they include a bronchoscopic approach by endobronchial valves, coils, and sclerosing 
therapies.47  
The National Emphysema Treatment Trial (NETT) explored the quality of a 
patient’s wellbeing in relation to medical and surgical therapies for patients with severe 
emphysema.48 The NETT found that after undergoing a pulmonary rehabilitation 
program, the Quality of Well-Being Scale (QWB) score significantly improved. Then, the 
patients were divided into the medically managed group and into the LVRS group, where 
the scores were measured over a series of months after receiving further treatment. This 
study concluded that a subgroup of patients who underwent maximal medical therapy and 
LVRS had greater improvement in their health-related quality of life. The NETT also 
explored and concluded how important it was to include and treat other cofactors in 
patients with severe emphysema, such as nutrition, cardiovascular disease, anxiety, and 
depression.39 The incidence of undernutrition in stable emphysema patients is between 20 
and 35 percent.39 The factors that lead to undernutrition include poor oral intake from 
early satiety, increased work of breathing, and chronic systemic inflammation. Stable 
emphysema patients, with a healthy body mass, have a higher resting oxygen 
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consumption when compared to healthy individuals.49 Undernutrition is an important 
factor to consider and remedy by increasing caloric intake for emphysema patients, as 
body mass index (BMI) is one of the factors that determines a patient’s mortality utilizing 
the BODE score.  
Patients who rely on oxygen supplementation have been found to have worse 
dyspnea, exercise tolerance, quality of life, and higher mortality. The LOTT study 
investigated the benefit of oxygen supplementation in COPD patients with moderately 
low levels of oxygen saturation within their blood.50 While there is research supporting 
oxygen supplementation in COPD patients with severely low levels of oxygen saturation, 
this study expanded on the long-term benefit of oxygen use in patients with moderately 
low levels of oxygenation within their blood. Moderately low levels of oxygenation 
included patients who had 89 to 93% oxygen saturation at rest or <90% during the 6-
minute walk test (6MWT). The study concluded that oxygen supplementation was not 
beneficial to COPD patients with moderately low levels of oxygenation as their survival 
rates and hospital admissions remained unchanged. Also, there were no changes in the 
patients’ lung function, quality of life, anxiety, depression, or short distance walking 
when compared to the control group.  
Emphysema patients are at increased risk of developing pneumonia due to the 
enlargement of the alveoli and an inability to clear out mucus buildup and bacteria from 




Patients who are discharged from the hospital following a COPD exacerbation are 
often sent to a pulmonary rehabilitation program. This comprehensive program provides 
patient education regarding their disease process and ways to improve their quality of 
life, which includes tailored exercises. These exercises provide the patient the ability to 
train their respiratory muscles for easier breathing. The patients will continue to use 
bronchodilators and inhaled corticosteroids, which reduce airflow obstruction and 
inflammation. For those patients who specifically have AAT deficiency, there is an 
option to have AAT replacement therapy. All patients are evaluated for the 
appropriateness of lung volume reduction surgery, where lung tissue is removed to 
decrease lung volumes and optimize diaphragmatic function. 
In regards to prognosis, risk factors that are associated with increased mortality 
include older age, supplemental oxygen use, lower total lung capacity percent predicted, 
higher residual volume percent predicted, lower cardiopulmonary exercise test workload, 
more emphysema present in the lower lung zones, decreased upper to lower lung zone 
perfusion, and modified body mass index (mBODE).39  Diagnosis of emphysematous 
changes within the lung parenchyma can be a more important prognostic component than 
FEV1. Another study determined that the prognostic factors of BMI, FEV1, dyspnea scale, 
and the 6MWT were better indicators of predicting risk of death compared to other 
factors.52 In regards to the mBODE, an increase by more than one point from baseline 
was associated with a higher risk of mortality, while any decreases improved predicted 
survival. Another retrospective cohort study found that when compared to patients with 
asthma with or without emphysema and COPD patients with or with emphysema, having 
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the co-diagnosis of emphysema with COPD was a greater predictor of death.53 
Independent prognostic factors for this subgroup of patients included older age, low BMI, 
and FVC. This subgroup was also more likely to die from de novo lung cancer with cause 
of death for one-third of the subgroup being malignant disease and one-fourth being due 
to lung cancer. Therefore, emphysema is a positive risk factor for lung cancer. Given that 
the diagnosis of emphysema is an important indicator of mortality, the goals of therapy 
should include and focus on preserving body weight and lung function, while monitoring 
for lung cancer. Lastly, complications of the disease can lead to HF, cor pulmonale, 
pulmonary emboli formation, pneumonias, and permanent respiratory insufficiency. 
 
Pulmonary Rehabilitation Programs  
Pulmonary rehabilitation programs are an initiative to continue patient education and 
optimize the quality of life for patients who are stable with regards to their irreversible 
chronic lung disease process. These programs are usually prescribed to patients who have 
been newly diagnosed with COPD, following clinical decompensation from a COPD 
exacerbation or patients with COPD who have had a functional decline. The patients 
usually attend a three-month long program at a supervised center where they work on 
exercise training, education, obtain psychosocial and nutritional evaluations, and 
treatments three times a week.39 These centers have to be equipped with enough space to 
allow for exercise on proper and safe equipment and also space for lectures. Exercises 
that are universally included within the program include cycle ergometer training, 
treadmill training, upper and lower extremity strength training, breathing therapies, and 
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relaxation therapies.52 These rehabilitation programs are usually held in a community-
based center, providing patients access to other peers who experience a decrease in 
quality of life as a result of their ongoing disease process. This fosters a sense of 
community to socialize amongst their peers.  
Multiple questionnaires and scoring systems are utilized during the program to 
ensure that patients are experiencing an improvement in their ability to function in 
everyday life. The goals of these multiple questionnaires are to evaluate the patient’s lung 
function, exercise tolerance, level of dyspnea, and quality of life over a period of 
intervals to track improvement in the patient’s capacity and progression of their disease. 
The questionnaires are divided into generic questionnaires and disease-specific 
questionnaires.36 
Generic questionnaires include those that are applicable to multiple diseases in 
order to assess the patient-centered outcome. For COPD patients in pulmonary 
rehabilitation programs, those questionnaires include 36-item Short-Form Healthy Survey 
score  (SF-36), EuroQol-5 Dimension Questionnaire (EQ-5D), and Hospital Anxiety and 
Depression Scale (HADS).54 The SF-36 is a generic assessment utilized to measure the 
patient’s quality of life and can be used in chronic disease states other than COPD. It is a 
36-item questionnaire, where the patient self-assesses the following domains in relation 
to their overall health: physical and social function, mental health, energy and vitality, 
health perception, physical and mental role limitation, and overall pain.36 This 
questionnaire represents an accurate response from the patient in regards to their specific 
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disease progression, with evidence of improved response after completing a pulmonary 
rehabilitation program.36,54 
Disease-specific questionnaires are focused on specific outcome measures for 
COPD patients enrolled within a pulmonary rehabilitation program and fall under the 
categories of quality of life measurements, symptom evaluation, depression and anxiety, 
functional status, exercise performance, physical activity, and knowledge and self-
efficacy.54 Questionnaires that measure the patient’s quality of life before, during, and 
after completing a pulmonary rehabilitation program include the St. George’s Respiratory 
Questionnaire (SGRQ), the UCSD Shortness of Breath Questionnaire (UCSD SOBQ 
score), the CAT score, and the Chronic Respiratory Disease Questionnaire (CRQ). The 
SGRQ is a 76-item questionnaire completed by the patient in the domains specific to 
COPD of symptoms, activities, and psychosocial impact.36 The maximum number of 
points that can be calculated is 100. The benefit of this questionnaire is that it accurately 
assesses interventions and results when implemented in COPD patients as a secondary 
outcome.36 However, there are multiple limitations that are associated with this 
questionnaire including length of time to complete, scores influenced by specific 
demographics of the patient, and variability in reported group versus individual minimal 
important difference (MID).36,54 The UCSD SOBQ score measures the quality of the 
patient’s dyspnea during daily activities through a 24-item questionnaire.55 It has been 
found to be useful in both the clinical and research settings and can be completed easily 
by the patient.55 CAT is a recently developed single scored questionnaire that assess a 
few aspects of the patient’s health status.54 While it does not capture the entire image of 
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the patient’s health, it is an effective and user-friendly assessment for both clinician and 
patient and can be used in combination with other questionnaires. Lastly, the CRQ is a 
20-item interview where the patient is asked disease-specific questions regarding their 
level of dyspnea, emotional function, and fatigue.36 The benefit of this interview is that it 
asks the patient to reassess the last five activities that caused them to have DOE and 
accounts for the effects of therapy. Symptom evaluation questionnaires include the 
previously mentioned SGRQ, CRQ, and CAT scores where the patient’s symptoms of 
their chronic disease, such as cough, dyspnea, fatigue, weakness, lack of sleep, and 
psychological state are assessed based on the patient’s perception of their current disease 
state. 
Depression and anxiety occur in up to 40% of COPD patients and, therefore, it is 
imperative to include these measurements within a pulmonary rehabilitation program.54 
The NETT study identified that overall function capacity was lower in patients with 
depression and anxiety when compared to those without psychological symptoms.54 Also, 
the ECLIPSE study found that patients had depression and worse 6MWT and SGRQ 
scores.54 Scales used to assess functional status include the Manchester Respiratory 
Activities of Daily Living Scale, Pulmonary Functional Status and Dyspnea 
Questionnaire, Pulmonary Functional Status Scale, the London Chest Activity of Daily 
Living (LCADL), and the Canadian Occupational Performance Measure (COPM).54 
These assess the patient’s ability to complete their daily activities based on ease. Other 




Exercise performance is assessed with the 6MWT, treadmill, and cycle ergometer 
tests, which are all utilized in a pulmonary rehabilitation program.54 The 6MWT is a self-
paced field walking test that assess how far the patient can ambulate in six minutes. It 
requires little equipment, has been found to correlate well with the SGRQ score, and is a 
better test for functional capacity.39,54 Another study found the 6MWT to be more 
sensitive when compared to cardiopulmonary exercise test when assessing for oxygen 
desaturation.52 There is the potential for this test to become a diagnostic test for patients 
to reveal dynamic hyperinflation or exercise-induced hypoxemia. The other functional 
tests, which include the treadmill and cycle ergometer tests, require equipment and 
patients who are physically fit enough to safely exercise on the equipment. These tests 
can assess for other physiological data when compared to the 6MWT. While the 6MWT 
is more commonly used, the decision to use a specific test is based upon cost, time, 
availability, knowledge, and specific outcome measurements. Physical activity is 
specifically measured through the use of questionnaires, energy expended, and motion 
sensors. Lastly, the patient’s awareness of their disease, progression, and supportive 
therapies is assessed through the Lung Information Needs Questionnaire (LINQ), the 
Bristol COPD Knowledge Questionnaire (BCKQ), the COPD Self-Efficacy Scale 
(CSES), and the Pulmonary Rehabilitation Adapted Index of Self-Efficacy (PRAISE).54 
These questionnaires have shown to be a reliable assessment of tools for determining the 
patient’s understanding of their disease in order to direct the educational module within a 
pulmonary rehabilitation program. 
	
28 
Other disease-specific scales include BODE Index and the Modified BORG 
Dyspnea Scale. The BODE index accounts for the patient’s body mass, amount of airflow 
obstruction and dyspnea in relation to exercise -- the higher the index score, the higher 
the patient’s mortality.56 In one study, the BODE index was found to be a better predictor 
of mortality when compared to the FEV.56 The BORG scale is utilized as a scale from 
zero to ten for the patient to assess their level of dyspnea. This scale is usually utilized 
during the exercise portion of pulmonary rehabilitation programs in order to assess the 
patient’s perception of their activity level in relation to their disease and level of dyspnea. 
After completing the three-month long series of sessions, patients are expected to 
continue the therapies and exercises they have learned at home. To ensure long-term 
maintenance of what the patients learned and worked on during their program, regular 
phone calls can allow the program to check in on the patients, and monitor how they are 
progressing with their rehabilitation plan. After completing a program, patients have been 
found to have an increase in their exercise capacity, improvement in dyspnea, and 
significant enjoyment in their overall quality of life.39 Specifically those who enroll and 
complete their first rehabilitation program are found to have greater improvement in 
multiple aspects that are measured while they complete the program, which includes 
maximal work, 6MWT, SGRQ, UCSD SOBQ score, and SF-36.39 Patients also 
experience an overall improvement in their physical conditioning, emotional well-being, 
and general health perception.  
The benefits of attending a pulmonary rehabilitation program include alleviating 
symptoms and improving functional capacity and overall quality of life.39 By the time 
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patients leave their program, they can move from one exercise group to the next. In one 
study, 13.5% of patients in one study moved from the low-exercise subgroup to the high-
exercise subgroup.39 These rehabilitation programs also offer patients the chance to 
become better candidates for other therapy options, such as LVRS.54 The exercises and 
education learned in the program optimizes the patient’s baseline function in the hopes 
that they will have a smoother recovery post-surgical therapy if that is a treatment 
modality they are pursuing. One study found that this improved global cognitive function 
in regards to visuomotor sequential skills and visual memory and decreased in anxiety 
and depression.39 
 In order to obtain all of the benefits of the program, the patient has to be 
compliant with not only attending their scheduled sessions, but also working on the skills 
they have learned at home. Risk factors associated with poor compliance within the 
program and, therefore, a less significant improvement in their symptoms include lower 
educational background, anxiety or depression, and distance needed to travel to the 
program.39 Another study evaluated which type of COPD patient will continuously attend 
a pulmonary rehabilitation program and found that male patients without emphysema and 
a history of smoking cessation were more likely to continuously attend the program.57 
 Overall, pulmonary rehabilitation programs are an integral component of 
providing a whole-body therapy approach to patients with emphysema. They have even 
been found to be beneficial even in patients with severe emphysema, stage GOLD 4.39 
Patients who attend and complete their pulmonary rehabilitation program were found to 
have a 61% survival rates after six years, which compares to 56% in those not 
	
30 
participating in the program.52 A known risk factor for developing COPD includes 
smoking and attending a pulmonary rehabilitation clinic usually encourages patients who 
currently smoke to stop, which increases the benefits obtained from the program.57 
 
Yoga 
Yoga is a five-thousand-year-old practice and one of the six Eastern orthodox systems of 
Indian philosophy that has evolved in the West as a modernized approach to the 
traditional way of breath work, meditation, and movement.58 The term yoga comes from 
the Sanskrit word of ‘yuj’, which carries many meanings including to yoke, bind, join, or 
attach.58 This term also carries the meaning of community or union. While the term 
‘yoga’ contains all of these meanings, in its essence, yoga means to bridge the body and 
soul of oneself to connect within the community. It offers the sense that the individual is 
a whole being, surrounded and supported by their community. There are eight core 
stages, or limbs, of yoga, as originally established by Patanjali in The Yoga Sutras.59,60 
These stages are an outline for people who practice yoga, otherwise known as yogis, to 
follow on their own path to self-enlightenment. The ascending stages are the following: 
yamas (the five moral restraints), niyamas (the five observances), asana (yoga poses), 
pranayama (mindful breathing), pratyahara (turning inward), dharana (concentration), 
dhyana (meditation), and samadhi (union of self with the object of meditation).60 It is 
through these stages that the yogi is able to learn and apply all aspects of yoga within and 
outside of a structured yoga practice. This path is not supposed to be completed in a 
linear order. Instead, it is used to influence the focus within the practice of asanas. 
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 In the Western culture, yoga is a form of exercise for most, a mechanism to de-
stress for some, and a form of meditation for others. While it is a commonly believed to 
be only accessible to those with high levels of flexibility, yoga, in its essence, is available 
and can be utilized by all individuals. There are many different styles of yoga classes and 
philosophies. Some of the more well-known yoga styles within the Western culture 
include anusara, ashtanga, bikram, hatha, Jivamukti, Kundalini, Iyengar, pre-natal, 
restorative, vinyasa, and yin. These class styles range from a slow, seated flow, to a more 
athletic and endurance type of class. There are also different styles of yoga breath work 
that can be used within a yoga class. The third limb of yoga is mindful breathing, 
otherwise known as pranayama.60 Ujjayi pranayama is a form of mindful breathing that 
involves the creation of a humming or oceanic sound during the extended expiration 
phase. Brown, MD in The Healing Power of Breath believes that the humming sound 
produced during the exhalation creates vibrations within the larynx that stimulate the 
sensory receptors of the vagus nerve to produce a state of total body relaxation.61 This 
form of breathing is sometimes referred to as ‘the breath of fire’ in a yoga class and can 
be utilized during the entire duration of a 60-minute or 90-minute vinyasa class. Other 
various styles of pranayama include nadi shodhana pranayama (alternate-nostril 
breathing), kumbhaka pranayama (breath retention), and kapalabhati pranayama (skull-
shining breath).62,63 There is a standardized approach to incorporating pranayama with the 
asanas while teaching a yoga class. In a class, inhalations are used when there is a lifting 
or opening of the chest, while exhalations are used during forward folds and twists. The 
objective of linking breath to movement is to create harmony within the body to 
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encourage a fully relaxed state of being. While the appeal of practicing yoga does include 
the benefits of being able to achieve various poses through the asanas, the real work of 
the practice is achieved by continuously practicing awareness of breath during the 
difficulty of the poses. There is a style of yoga for everyone with the ultimate goal of 
matching breath to movement to bring awareness to oneself. 
 In our Western culture, yoga is held in yoga studios, fitness centers, resorts, 
vacation-styled retreats, prisons, schools, and multiple work sites. There is an appeal of 
yoga in that practicing yoga may provide a mechanism to de-stress, unwind, become fit, 
and practice a sense of peace within a constantly working, evolving, and progressing 
society. Businesses and employers may offer complimentary yoga classes to its 
employees to provide a way to de-stress, while schools offer classes to students to obtain 
mindful exercise. Overall, yoga can be practiced anywhere, and as a society, we have 
made it available as a customized practice for many different social groups.  
 In Rolf Gates’s book, Meditations from the Mat,60 he expresses within the first 
chapter that through the practice of yoga, one can achieve balance in their life. He 
explains that the popularity of yoga within the Western culture has grown tremendously 
within the 21st century due to the fact that humans are looking for a solution to find 
balance within our constantly changing and demanding world. He continues to explain 
how yoga is a practice that honors what life is, in the sense that humans are on a lifelong 
journey to recognize and then enjoy their own individualized essence. In William J. 
Broad’s book, The Science of Yoga: The Risks and the Rewards, he deems the rise in the 
popularity of yoga is due to the fact that yoga is an ancient form of finding peace that 
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forces people to become unplugged and provide time to tune out the constant overflow of 
information in order to turn inward.64 In B.K.S Iyengar’s book, Light on Yoga: The Bible 
of Modern Yoga,58 he expresses the appeal of yoga to be due to obtaining the sense of 
feeling complete. His understanding of yoga is deeply rooted within the Indian 
philosophy and the liberation of the human spirit. Just as there are many different 
philosophies and beliefs regarding yoga, both ancient and modern, there are just as many 
of different types of yoga. It is through one’s own interest that a specific type of yoga 
philosophy, style, and benefits can appeal to the individual to provide them the benefits 
they want to accrue through their practice. 
 For those who practice yoga, each individual has their own reason why they 
continuously return to their practice. An individual may see or feel benefits from an 
established yoga practice such as reduced joint pain, reduce low back pain, increase in 
flexibility, and potentially a thinner and toned physique.60 While these are all physical 
benefits, there are also mental, emotional, and spiritual benefits unique to each individual. 
For a philosophy that is based on Eastern tradition, there have been efforts to create 




Current research on the health benefits of yoga include those of yoga asanas and 
pranayama for healthy individuals and those with chronic diseases, such as COPD, and 
	
34 
coronary artery disease, along with complications from obesity, stroke, anxiety, and 
depression.19,65–69  
 In a healthy male, a consistent yoga practice of alternate-nostril breathing has 
been found to reduce systolic blood pressure (SBP), heart rate (HR), and respiratory rate 
(RR).17 A study of 26 healthy young male volunteers who participated in alternate-nostril 
breathing and breath awareness for 25-minute sessions found an increase in vagal nerve 
activity during and after alternate-nostril breathing. An overall decrease in HR was 
measured during the alternate-nostril breathing session (p<0.05, 95% CI: -0.583, -
74.001), while a significant increase was measured after the session (p<0.001, 95% CI: -
0.023, -0.094).62 There was a decrease in SBP (p<0.05, 95% CI: 10.381, 0.712) and RR 
(p<0.001, 95% CI: 5.205, 2.309) and in RR after (p<0.001, 95% CI: 2.265, 0.531) the 
alternate-nostril breathing session.62 Overall, the study found that SBP decreased by an 
average of 4.5mmHg, along with a decrease in RR during and after alternate-nostril 
breathing and breath awareness.62 This study was limited in the small sample size of 
males who were enrolled, which increases the difficulty of recapitulating with larger 
sample sizes and decreases the generalizability of the study. Another study investigated 
the reduction in blood pressure in patients with HF who participated in yoga. The 
participants were involved in both unspecified yoga movements and breath work for the 
duration of 12 weeks and there were significant decreases in blood pressure and HR in 
the intervention group compared to the control group.17 There are multiple studies that 
explore how yoga decreases blood pressure in hypertensive patients, however, when 
investigated in a meta-analysis, the results found that the evidence was of low quality to 
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support the modality of hypertensive therapy to include yoga, prompting further research 
in this area.70 Yadav et al. observed a reduction in the Framingham Risk Score (FRS) and 
10-year cardiovascular disease risk when yoga movement, breath work, and meditation, 
along with relaxation techniques, stress management, support group, and nutritional 
counseling were implemented within a single-arm, pre-post interventional study.14 The 
intervention lasted ten days, and the 386 participants were encouraged to also incorporate 
these various techniques within their daily lives. Following this short-term intervention, 
the FRS (p<0.001) and estimated 10-year cardiovascular risk (p<0.001) were 
significantly reduced by 15% and 11% respectively. This study was limited by the 
nonrandomized, single-arm, historical cohort design with no control group, the study 
subjects including low to medium cardiovascular risk patients of the Indian population, 
and the results included short-term benefits instead of the long-term benefits. While this 
study was structured as a short-term interventional study, the results prompt further 
research for a long-term intervention.  
 The International Journal of Yoga conducted a PubMed bibliometric analysis to 
assess the yoga literature on cardiovascular health.71 From 1961 onward, there was an 
increase in the amount of studies regarding yoga intervention to improve cardiovascular 
health with the years 2011 and 2014 contributing the most studies per year. The majority 
of these studies were conducted in the United States and India and included randomized 
controlled trials, nonrandomized controlled trials, and single group studies. The 
participants within these trials ranged from healthy individuals to geriatrics, those with 
chronic diseases of diabetes, hypertension, and coronary artery disease. The majority of 
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the studies lasted 12 weeks with a range of 8-56 weeks. This analysis was similar to a 
prior analysis conducted by Ugolini et al. in that a majority of the studies regarding yoga 
intervention for cardiovascular health involve healthy participants over a short-term 
intervention.72 There is a need for more high-quality evidence on the cardiovascular 
benefits from a consistent yoga practice in regards to blood pressure, lipid levels, and 
clinical events. In a Cochrane review, yoga was reviewed for its effects as a primary 
prevention for cardiovascular disease.19 In 11 trials, yoga was found to have a significant 
effect on decreasing diastolic blood pressure (DBP) (mean difference -2.90 mmHg, 95% 
CI: -4.52 to -1.28), HDL cholesterol (mean difference 0.08 mmol/l, 95% CI: 0.02 to 
0.14), and triglycerides (TG) (mean difference -0.27 mmol/l, 95% CI: -0.44 to -0.11).19 
Yoga was not found to make a significant effect on low-density lipoprotein (LDL) 
cholesterol (mean difference -0.09 mmol/l, 95% CI: -0.48 to 0.30).19 This review is 
consistent with prior reviews in that the majority interventional studies using yoga are 
structured as short-term interventions with a small group of participants. This continues 
to support the gap in current research that long-term studies with more participants and a 
standardized, descriptive yoga intervention is included for those with chronic diseases, 
such as cardiovascular disease. Lastly, there was also multiple cases of potential 
performance bias explored in this review, which calls for higher quality of study design 
for future research.  
 Not only has yoga been explored for prevention outcome of chronic diseases, 
yoga has also been introduced as rehabilitation for long term disabilities, such as for 
patients who have sustained a stroke. In another Cochrane review, two randomized 
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controlled trials, one conducted in the United States and another in Australia, investigated 
the primary outcome of quality of life, along with secondary outcomes of movement, 
anxiety, depression, and disability when yoga was used as part of a stroke rehabilitation.20 
Overall, there was no significance of yoga as an intervention in quality of life, balance 
(mean difference 2.38, 95% CI: -1.41 to 6.17, p=0.22), gait (mean difference 1.32, 95% 
CI: -1.35 to 3.99, p=0.33), motor function (mean difference -4.00, 95% CI: -12.42 to 
4.42, p=0.35), disability (odds ratio (OR) 2.08, 95% CI: 0.50 to 8.60, p=0.31), depression 
(mean difference -2.10, 95% CI: -4.70 to 0.50, p=0.11), or trait anxiety (mean difference 
-6.70, 95% CI: -15.35 to 1.95, p=0.13).20 However, the review reported a significance 
difference in state anxiety (mean difference -8.40, 95% CI: -16.74 to -0.06, p=0.05), 
though overall, the data in this review was deemed of low-quality. Based upon the small 
size, low-quality, and risk of bias in these studies, there is a need for higher quality 
studies to investigate this further.  
 One reason people turn to yoga is that it is a healthy coping mechanism for 
dealing with the stressors of everyday life. In patients with chronic disease, one of the 
complications that they have to cope with is the development of anxiety and depression 
associated with their diagnosis. In a study by Franklin et al., asanas were found to be 
associated with a decrease in overall depressive symptoms, even in the setting of 
increasing life stressors.73 A Japanese randomized controlled study investigated the effect 
of facial exercises in a geriatric population and its effect on their overall mental health.74 
Though the majority of the participants were female, there was an overall improvement in 
mental health and mood in the intervention group. These studies may promote future 
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investigations on the effect of yoga as an intervention on the mechanism of psychological 
distress. When integrating yoga movement and breath work in a group of teenagers in an 
acute psychiatric inpatient unit, there was an overall reduction in anxiety with an increase 
in mood.75 While this study did not have a control group, the entire cohort of participants 
either incorporated one intervention (yoga movement) or multiple (yoga movement, 
breath work, meditation, and relaxation techniques). This study potentially supports the 
efficacy of the intervention and encourages further studies to include a control group with 
randomization.  
 In a study conducted in India, the use of right-nostril breathing along with various 
yoga asanas was implemented in a group of 32 obese female participants, aged 18-25, to 
assess for psycho-physiology changes.76 The participants completed the breathing 
exercise for ten minutes a day, four times a day, along with asana practice for a period of 
thirty days. The study found that the combination of breath work and yoga movement 
created positive psychological changes within the participants, while decreasing the risk 
for obesity associated complications. Another study investigated the positive effect 
intermittent breath holding had on response inhibition for healthy volunteers as a way to 
introduce this intervention for those in the setting where response inhibition is altered.77 
A randomized controlled trial that investigated the effects of pranayama on pulmonary 
function in healthy individuals for a duration of twelve weeks found a significant 
improvement (p<0.05) in PFT (FEV1, FVC, and FEV1/FVC ratio) of the intervention 
group when compared to the control group.63 While this study was performed in healthy 
teenagers, the findings can support the development of similar studies in a specific subset 
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of patients. Another form of pranayama, such as high frequency yogic breathing, was 
implemented within a study of breath awareness.78 The results of this study suggested an 
increase in right-hand grip strength, along with improvement in finger and arm tapping.78 
Yoga breathing can even be implemented in preoperative rehabilitation for lung cancer 
patients.79 Not only did yogic breathing improve the participants’ PFT prior to surgery, it 
helped reduce cigarette cravings, which has been found to decrease postoperative 
complications. Another review that assessed the effects of various types of yogic 
breathing found that when slow-paced pranayama was compared to fast-paced pranayama 
for a period of three months, slow-paced pranayama reduced sympathetic activity, and 
increased parasympathetic activity.80 An additional review of studies from 1988 to 2016 
made similar conclusions.13 In a randomized controlled trial of postgraduate students, the 
use of pranayama for one semester resulted in lower test anxiety in the intervention group 
(33%) when compared to the control group (66%).81 Yoga has a positive effect on the 
autonomic nervous system, promoting relaxation by increasing the parasympathetic 
response while decreasing the sympathetic response. 
 A review by Richardson et al. that summarized the benefits of in-person 
rehabilitation programs for chronic cardiac and pulmonary diseases introduced the 
potential for incorporating alternative methods of therapy into the programs. These 
programs included tai chi and yoga as a way to provide motivation for patients to attend a 
program and maintain their physical activity level after completing the program.18 This 
review found that utilizing the patient’s time during their attendance in the rehabilitation 
program to promote the continuation of a healthy lifestyle with community-based 
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physical activity is a very important goal, especially for those with COPD. Small study 
meta-analyses showed benefits of both tai chi (p<0.01) and yoga (p<0.01) in the 6MWT 
when compared to the standard level of care. Few studies listed these therapies as an 
additional or a replacement therapy to the standard level of care and there were no studies 
on the use of these mind-body activities as maintenance therapy when the program was 
completed.18 In this regard, there is a need for better designed studies that incorporate a 
larger group of patients and utilize questionnaires other than the 6MWT during the 
rehabilitation programs with further standardization, while incorporating other 
populations, as a majority of these studies have been conducted in Chinese and Indian 
populations. A pilot study had non-yoga instructors educate COPD patients on how to use 
pranayama to avoid attending pulmonary rehabilitation programs.66 The primary outcome 
was the 6MWT, which increased from baseline in the intervention group to 28 meters 
(95% CI: -5 to 61, p=0.06) and decreased from baseline in the control group by 15 meters 
(95% CI: -47 to 16), though not clinically significant (p=0.06). This further supports the 
need for a more structured intervention in a larger cohort of participants. Another study 
randomized COPD patients into four groups -- drug therapy, traditional qigong training, 
modern rehabilitation training, and integrative respiratory rehabilitation training -- and 
measured improvement in the 6MWT, CRQ, and BORG score as the primary outcome.82 
After six month and one-year of treatments the integrative respiratory rehabilitation 
training group had an overall improvement in all outcomes when compared to the other 
three groups. This may indicate an importance of time dependency for integrative 
respiratory therapy and promote future studies on the long-term use of this technique. In 
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another Cochrane review on breathing techniques in COPD patients, sixteen studies 
found an improvement in the 6MWT after practicing either pursed lip breathing, 
diaphragmatic breathing, or timed pranayama breathing.83 While there was an 
improvement in the primary outcome measurement, there was no consistency regarding 
improvement in the participants’ level of dyspnea or quality of life. In another 
randomized controlled trial, COPD patients in the intervention group used a respiratory 
biofeedback system to visually express the desired breathing pattern while obtaining 
training in controlled breathing techniques.68 At the end of the four-week study, there was 
no significant difference between the two groups in regards to the primary outcomes of 
FEV1 (mean difference -0.8%, 95% CI: -4.4 to 2.9%, p=0.33), 6MWT (mean difference 
12.2m, 95% CI: -37.4 to 12.2m, p=0.16), CRQ (mean difference 0.2, 95% CI: -0.1 to 0.4, 
p=0.11), and cardiac autonomic function (mean difference 2.2ms, 95% CI: -20.8 to 25.1, 
p=0.51).68 There are many different breathing techniques, including various styles of 
yogic pranayama, that yield various results when applying them to a specific participant 
population, such as COPD patients. 
 The literature review here reveals that various styles of yogic pranayama and 
movement have been implemented in various studies for chronic conditions, such as 
cardiovascular disease and COPD, along with complications from obesity, stroke, 
depression, and anxiety. In the last few years, there has been an overall increase in 
research involving yoga and its benefits on the cardiovascular system. However, in 
multiple reviews, the sample sizes of these studies were small and the duration of the 
studies were short-term. Additionally, there were few high-quality randomized controlled 
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trial studies investigating the beneficial effects of yoga on multiple body systems. Thus, 
the results in the literature may have been affected by the bias of the researchers or 
participants within these studies. In regards to the participant population within these 
reviews, there was variability in the healthy participants versus those who had co-
morbidities. Another limitation is the variation of yoga utilized within a study, such as the 
style of yoga, the intensity of the practices or interventions, the experience of the yoga 
instructors included within the studies, and the level of depth provided in the study 
methods regarding these details. There are a few short-term randomized controlled trials 
implementing hatha yoga or yoga pranayama for COPD patients, however, none of these 
trials specifically investigated the effect on emphysema patients, compared conventional 
pulmonary rehabilitation program to a combination of yoga breathing technique and 
exercise, or a year’s worth of patients who participated in one single pulmonary 
rehabilitation program. 
The pulmonary rehabilitation program studies are generalizable to the COPD 
patient population because that is the ideal participant who will attend that program. In 
regards to the literature review on yoga interventions, there is a higher probability that 
these findings are not generalizable as there is a variety in the types of participants 
included in trials with the intervention of yoga. Studies included both healthy 
participants, those with co-morbidities such as cardiovascular disease, and COPD 
patients. Thus, these findings suggest that implementing yoga within chronic disease 
therapy could reduce progression of the disease process. The proposed study will 
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evaluate for a more specifically designed and long-term study to obtain the benefits of 








This project will be a randomized controlled trial in which COPD patients will be 
randomized to participate in yogic breathing and movement as part of their pulmonary 
rehabilitation program or to a standard pulmonary rehabilitation program. Once the 
patients have been recruited, half will be randomly assigned to the control group, ‘Group 
A’. This group will complete the entire rehabilitation program with no additional 
intervention. The second half of the patient group will be assigned to the treatment group, 
‘Group B’. These patients will complete the rehabilitation program with the additional 
intervention of yogic breathing and chair yoga movements. Randomizing the patients will 
be performed by using Microsoft Excel by an individual who is not affiliated with the 
pulmonary rehabilitation program, the patients’ treatment teams, or the patients. The 
patients will be informed of their group assignment by placing the information in a sealed 
plain white envelope with their name on the front of the envelope and handed to them. 
The patient’s clinician who evaluates them at regular intervals during the duration of the 
trial to assess their pulmonary function status will be blinded to the study arm to which 
the patient was randomized to reduce measurement bias.  
 
 Study population and sampling 
The patient pool will include the patients who attend the pulmonary rehabilitation 
program at the university hospital of Boston University (BU), Boston Medical Center 
(BMC), within a given year. By sampling patients from this very specific population, 
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they have already been screened as the ideal candidate for this study. Specifically the 
inclusion criteria are that the patient for this study: will have a confirmed diagnosis of 
mild-to-severe COPD, based on the GOLD criteria; is aged 18 years or older; has a BMI 
between 18 kg/m2 and <40 kg/m2; is deemed clinically stable, meaning they have had no 
recent changes in the progression of their disease or step-up in any of their at-home 
medications over the last month; has had no history of cardiac or thoracic surgeries; and 
is not diagnosed with any other pulmonary pathological diseases besides COPD. Patients 
who may need to use supplemental oxygen or those who have been enrolled and 
completed a pulmonary rehabilitation program prior will be included within this study. 
Exclusion criteria include those patients who have severe physical limitations, where they 
are unable to move any of their limbs on their own due to neurological or visual 
disorders, which would prevent them from participating in the movement component of 
the pulmonary rehabilitation program, or those that have had a recent COPD 
exacerbation, where they were required to step-up in their at-home medication regimen. 
Other exclusion criteria include uncontrolled hypertension, orthostatic hypotension, 
history of previous myocardial infarctions, or other lung diseases.  
 The primary outcome of interest is that the patients experience an improvement in 
their overall quality of life, as measured by the 6MWT, SGRQ and SOBQ questionnaires 
within the one sample size, after completing a pulmonary rehabilitation program that 
implemented yogic breathing and movements within the framework of their outpatient 
COPD management. In order to calculate a sample size that would result in the findings 
being clinically significant, the following parameters were used; alpha 0.05, beta 0.20, 
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proportion of Group A 0.30, the number of subjects in each group is 50. Based on those 
parameters, the study has an 80% power to detect a benefit in Group B of 0.596.  
 
Intervention 
Group A is the control group for this randomized controlled trial. In this group, the 
patients will complete the pulmonary rehabilitation program with no intervention. This 
means the patients will attend the pulmonary rehabilitation program for three months 
with three sessions a week, with each session consisting of a one-hour long lecture about 
an informative topic regarding their disease or suggestions on how they can lead a 
healthy and happy life with their progressive disease process and an hour completing a 
full-body workout. The lectures will include topics such as the general disease 
progression of COPD, mechanisms of action for medications, supplemental oxygen use, 
how to clear secretions, stress management, nutrition, travel, energy conservation, and 
advanced directives. Workout sessions will include lower extremity endurance by 
walking on a treadmill or using an indoor bicycle and strength training with upper 
extremity exercises with the use of free weights or resistant bands.  During every workout 
session, the patient’s functional capacity will be measured by means of exercise 
tolerance, duration of exercise, intensity of exercise, amount of breaks taken, and whether 
supplemental oxygen was utilized. These factors will be recorded in the patient’s chart 
and tracked during each session. Over the course of the session, respiratory therapists will 
assess how the patient is performing and either encourage advancement in the endurance 
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of the patient’s exercise or recommend that the patient take a break prior to increasing 
their intensity level.  
Group B is the intervention group of this study in which the patients will be 
exposed to the educational model and practice of mindfulness through breath and 
movement by the mechanism of yoga. This group’s study will follow the conventional 
pulmonary rehabilitation program guidelines, similar to Group A. Group B will differ in 
regards to their exposure to the mindset of yogic breathing of ujjayi pranayama and two 
yoga chair sequences (Appendix I) for which they will be provided with techniques in 
which to implement and practice what they learned in lecture and guidance to make this a 
habit over the next three months. Not only will Group B learn information specifically 
tailored to their progressive disease process during the pulmonary rehabilitation program, 
these patients will also have lectures about yoga nidra, chair yoga, and different ways to 
implement mindfulness with breath in their day-to-day lives.  
 
Study variables and measures 
The primary outcome measures will include the questionnaire numerical values of the 
6MWT, which will assess for exercise tolerance, SGRQ, which will assess for stationary 
breathing, and SOBQ, which will assess for overall quality of life. The patient’s baseline 
for these three questionnaires will be established on the patient’s first day at the 
pulmonary rehabilitation center and reassessed at six weeks into their program and at 
their last session in the program at twelve weeks. The goal is to obtain an improvement 
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with all three questionnaires to lead to an overall improvement in the health quality of 
their life.  
 The project variables include the patient’s gender, age, BMI, severity of disease 
process, other mild to moderate co-morbidities, exercise tolerance level, and use of 
supplemental oxygen. These demographics will be obtained during the recruitment phase 
from a recruitment survey, where the data collected will be organized in Microsoft Excel 
and used to compare Group A and B at the end of the study.  
 Potential cofounders for this study include whether the patient had previously 
attended a prior pulmonary rehabilitation program, whether the patient attends all of their 
scheduled pulmonary rehabilitation sessions during their twelve-week duration with the 
program, the patient’s general awareness towards their disease progression, whether there 
is an episode of exacerbation or acute change in overall health during the study, the 
patient’s psychological state, and also social factors. The data on these factors will be 
collected and recorded during the course of the study within the patient’s chart. 
 
Recruitment 
During the patient’s first day at the pulmonary rehabilitation clinic at BMC during the 
time period of November 2019 to November 2020, the patient will be screened to 
determine if they are an appropriate candidate for the study. Then, the administrator will 
be tasked to ask the patient if they are interested in being a part of this study. Once the 
patient provides a verbal consent to complete the study, the administrator will help the 
patient complete a recruitment survey, where the patient will be provided the study 
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objectives, design, intervention, and risks and benefits, and the patient will provide their 
demographic information, contact information, and signature on the consent form. 
 
Data collection 
After the patient has been recruited into the program and completed the recruitment 
survey, the patient will be randomized into either Group A or B and will begin with an 
initial assessment by completing their 6MWT, SGRQ, and SOBQ questionnaires with a 
respiratory therapist. The respiratory therapist will record their data into a chart within the 
patient’s program binder and continue to do so after every session for the next twelve 
weeks. At weeks four, eight, and twelve, the patient will meet with the study physician 
who will review the data from the patient’s chart and repeat the patient’s questionnaires 
for their visit to determine if there is an overall improvement in the patient’s physical 
function. At the end of the twelve weeks, all of the patient’s data from their paper chart 
will be copied into a Microsoft Excel document, which will be combined with all the 
other patients randomized to that group, in order to assess the overall effect of the 
intervention. 
 Every twelve weeks, a set of new Group A and Group B participants will be 
enrolled into the study for a total duration of one year. Therefore, data collection will last 





Both groups will be assessed every four weeks by the patient’s clinician who is blinded to 
their specific intervention. The clinician will record their pulmonary function levels and 
track them over the three months the patient is in the program. At the end of the three-
month long program, there will be an analyst who will review the patients’ scores in 
relation to the recorded information by the clinician regarding the patients’ overall well-
being during their time in the pulmonary rehabilitation program. This is to assess whether 
or not the intervention for Group B was superior to the standard of care practiced in 
Group A. 
The complied data from both groups over the period of a year will be utilized 
from the Microsoft Excel document in order to test the hypothesis of this study. This data 
will be used to obtain the mean and standard deviations of Groups A and B in each 
hypothesis category -- exercise tolerance from the 6MWT questionnaire, stationary 
breathing from the SGRQ questionnaire, and overall health quality of life from the SOBQ 
questionnaire. These improvement values will be used to compare the significance of the 
yoga intervention measured by overall patient improvement in Group B compared to 
Group A. The data will be placed into a chi-square distribution for each questionnaire. 
Then, the OR for each questionnaire will be calculated to determine whether the patients 
in Group B are more likely to experience an overall improvement in their exercise 
tolerance, stationary breathing, and overall health quality of life as measured by the three 
questionnaires when compared to Group A. 
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Timeline and resources 
The estimated timeline for this study spans from September 2019 to December 2020 
(Table 3). The study proposal will be submitted to the IRB in September 2019. Approval 
from the IRB will take one to two months. Patients will begin to be screened and 
recruited into the study in November 2019, and will continue every twelve weeks for one 
year. At the conclusion of the study in November 2020, all data will be compiled together 
and analyzed in December 2020.  
Table 3. Proposed Project Timeline  
September 2019 November 2019 – 
November 2020 
December 2020 
IRB submission  
IRB approval  
Screen and recruit eligible 
patients into study  
 
Conduct study  
(12 weeks duration per 
group) 
 
Collect data  
Data analysis  
 
Since a pulmonary rehabilitation program approaches patient care from a 
multidisciplinary and individualized approach, an interdisciplinary team of healthcare 
professionals will be utilized for this study. The team will include one physician, three 
nurses, three respiratory therapists, two physical therapists, one psychologist, one 
exercise specialist who is a certified yoga instructor, and two administrators for one 
group of 12 patients with six patients per study arm per rehabilitation session of 12 weeks 
duration. Two groups of 12 patients will be processed every 12 weeks.  
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 This study will take place in the pulmonary rehabilitation center at BMC, where 
there is a lobby for patients to sit while they wait for their session to begin, a check-in 
area once the patient enters the center, chairs with oxygen tanks where the patients can sit 
while they wait for the respiratory therapist or physical therapist to instruct the patient to 
begin with their exercise workouts, indoor bicycles and treadmills for patients to 
complete their cardiovascular exercises, and free weights, resistance bands, and 
functional trainer cable machines for strength training. There will also be a conference 
room with a projector and a computer to comfortably sit all the patients in order to 
present each session’s educational lecture topic. Lastly, there is access to an elevator for 
those who require a wheelchair when accessing the pulmonary rehabilitation center. 
 
Institutional Review Board 
This study design includes data collection and analysis through non-invasive procedures 
based upon patients’ physical performance and response with the 6MWT, SGRQ, and 
SOBQ questionnaires, which meets 45 CFR 46.110 criteria to qualify for expedited 
Institutional Review Board (IRB) review. This study design will be submitted for 
expedited review to the Boston University and Boston Medical Center IRB.  





Once diagnosed, COPD is a lifelong disease in which therapy is focused on symptomatic 
relief. In order to prevent rapid progression of the disease or further exacerbations, the 
multidisciplinary approach to treatment aims to target the risk factors, symptoms, and 
complications. This study aims to explore the benefits of including yoga breathing and 
exercise techniques into the standard of care for pulmonary rehabilitation programs. The 
results will provide evidence for the use of alternate therapy options in chronic disease 
management of emphysema.  
  Based on this study proposal, there are a couple of anticipated obstacles that may 
be encountered. These include recruiting enough eligible patients to participate in the 
study, patients attending all of their scheduled pulmonary rehabilitation sessions and 
physician appointments, and full participation in all activities based upon the patients’ 
health statuses, i.e. no exacerbations.  
 This study design is better than those of the studies included in the literature 
review because the methods describe in detail the exact interventions that are being 
utilized on a specific subgroup of participants. While there are variations within the 
existing research regarding the level of health of the participants and the type of yoga 
intervention in regards to patient education, expert level of teaching, exercise intensity 
level, and type of breathing technique, this study not only explains those methods, it is 
also conducted over a longer period of time. This design will help obtain data to 
investigate the primary outcome, that the participants obtain an improvement in their 
	
54 
exercise tolerance, stationary breathing, and quality of life by implementing yoga 
breathing and exercise techniques within their pulmonary rehabilitation program model.  
 Some limitations of this study design include the lack of blinding and systematic 
errors in measurements. This study is a randomized controlled trial where participants are 
randomized into two groups; Group A which is the control group and Group B which is 
the intervention group. Since the participants will know which arm of the study they are 
allocated to, there is no opportunity to blind them to the intervention. The patients’ 
clinician who will assess the patients and administer the three questionnaires will be 
blinded to which group the patient is in, in order to avoid bias through data collection. 
Lastly, there could be systematic errors in measurement though data collection obtained 
from the three surveys and the data analysis. The three surveys may be opportunities for 
recall bias from the patients, question order bias in the order the questionnaires are asked, 
and systematic error in the comparison measurements of Group A to Group B. 
 
Summary 
COPD is a systemic disease that includes asthma, chronic bronchitis, bronchiectasis, and 
emphysema. In patients with emphysema, the pathology of their disease includes air flow 
obstruction and air trapping. Environmental pollutants lead to lung parenchyma damage, 
causing alveoli to enlarge and lose the ability to recoil. Over time, this increases the 
amount of air trapped in the lungs, which evolves into dynamic hyperinflation. In this 
state, the patient’s exhales shorten, increasing the amount of air trapping. Continually 
trapping air within the lungs will eventually lead to a decrease in the length of the exhale. 
	
55 
The patient will become dyspneic, leading to an increase in the work of breathing. This 
expends more energy, leading to fatigability, and concludes with a significant decline in 
exercise tolerance. All of these factors combined lead to an overall decrease in quality of 
life and increase in the rate of anxiety and depression. Therapeutic measures for patients 
with obstructive lung disease include a multidisciplinary approach that combines 
smoking cessation, pharmacotherapy with bronchodilators and anti-inflammatory 
medications, pulmonary rehabilitation programs, and at times, surgical intervention with 
lung volume reduction surgery or lung transplantation.  
 The focus of this study is to explore the offerings of pulmonary rehabilitation 
programs and incorporate a more mindful option for emphysema patients who attend the 
program. Pulmonary rehabilitation programs are important in addressing the physical 
decline of emphysema patients by targeting their symptomatic concerns through patient 
education lectures, exercises, and breathing techniques. Pulmonary rehabilitation 
programs are also beneficial for the patient by providing a social environment in which 
patients can interact amongst peers, and develop a sense of community. What is lacking 
within pulmonary rehabilitation programs and the literature is a specifically targeted 
mindful approach to incorporating yoga breathing techniques and exercises within the 
framework of the program.  
 While there are many yoga breathing techniques, the one utilized in this study is 
timed ujjayi pranayama. During this exercise, the patient is able to bring more awareness 
to the length of each inhalation and exhalation and has time to focus on lengthening their 
exhalation which will lead to a decrease in air trapping. This breathing style could 
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minimize dynamic hyperinflation by preventing early bronchiolar closure during the 
exhalations. This would provide more time for the emphysema patient to exhale more air 
and, therefore, minimize air trapping and hyperinflation. Over time, the patient may be 
able to exercise more and obtain further health benefits. This technique creates a 
meditative state, and can ease the patient’s overall anxiety and depression related to their 
disease. By creating these positive effects, the patient is more likely to continue with their 
exercises and breathing techniques they learned during their time in the pulmonary 
rehabilitation program. This will aid in slowing down the progression of their disease 
with the overall goal to decrease the amount of exacerbations they experience. This study 
will provide the opportunity to educate patients on how to approach their chronic disease 
more mindfully and to promote patient success by continuing their breathing techniques 
and exercises once they complete the program. This study will aid to fill the gaps in the 
current literature on the benefits of utilizing yoga techniques within the realm of 
pulmonary rehabilitation programs.  
 
Clinical significance 
This study aims to explore implementing yoga techniques of mindful breathing and chair 
yoga exercise into the current structure of pulmonary rehabilitation programs to show 
continued benefits for emphysema patients. The quantitative data will be complied into 
one comprehensive source that can be utilized to support the merging of yoga technique 
within the current standard of care incorporated within the pulmonary rehabilitation 
program framework. The results of this study can help promote incorporating mindful 
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activities such as ujjayi pranayama and chair yoga sequences into supportive therapy for 
emphysema patients. By providing more information regarding the use of yoga within 
general patient healthcare, this study can help expand other therapy management options 






EXAMPLE CHAIR YOGA SEQUENCES 
The following example chair yoga sequences can be integrated within the intervention 
group, Group B, for the exercise portion of the pulmonary rehabilitation program. The 
intention of these sequences is to be accessible by every participant in Group B with 
appropriate safety practiced. If a participant deems that a pose is not accessible, they are 
allowed to either modify that pose or practice their breath work. The poses are sequenced 
to be completed as five to ten repetitions for three sets, two to three days a week. The 
participant can begin with five repetitions and work their way up to ten repetitions over 
the course of the study. For poses that have two sides (i.e. a right and left side), start with 
the right side and then progress the sequence to the left side. A resistance band is an 
optional tool to increase resistance for the upper and lower body sequences. Equipment 
required for these sequences include a stable chair with or without arm rests and a 










CHAIR YOGA SEQUENCE 1 – UPPER BODY 
 
Seated Dandasana   Forward Arm Raise       Forward Arm Raise   
Seated Pose    Lateral Pull         Relax to Middle  




Seated Tadasana   Cactus Arms with Band  Seated Cactus Arms  
 




Inhale through nose  Exhale through nose          Inhale through nose 
	
 
Seated Bear Hug  Seated Dandasana           Seated Ustrasana 
Lift elbows   Seated Pose           Seated Camel Pose 




CHAIR YOGA SEQUENCE 2 – LOWER BODY 
 
Tadasana   Modified Utkatasana        Seated Dandasana 
Standing Pose   Modified Chair Pose         Seated Pose 
Inhale through nose  Exhale through nose         Inhale through nose 
 
Seated Urdhva Dhanurasana Seated Dandasana          Seated Apanasana 
Seated Wheel Pose    Seated Pose           Seated Knee-to-Chest Pose 
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Exhale through nose  Inhale through nose          Exhale through nose  
 
Seated Parsva Urdhva Hastasana with and w/o bind    Seated Agnistambhasana  
Seated Side Stretch               Seated Half Fire Log Pose 
Inhale raise arm, Exhale side stretch             Inhale bend knee, Exhale rotate 
 
Seated Dandasana   Vrikasana            Adho Mukha Svanasana 
Seated Pose    Tree Pose          Chair Downward Facing Dog 
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Inhale through nose   Inhale stand, Exhale place foot Exhale through nose  
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